Innovative RNA-based therapies
Our technology has the potential to be applied to a broad number of targets and across a range of tissues and diseases. Versameb is building a pipeline of promising new first-in-class RNA therapeutics leveraging a next generation platform technology as we progress our current assets towards the clinic.
Versameb is currently developing molecules targeting regulation of immune response and regeneration in the fields of immunological disorders, oncology and myology. The VERSagile platform technology is amenable to any nucleotide therapy, has been validated for these therapeutic targets, and preclinical proof of principle has been established with its lead assets in animal models
The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform.